Here are five key points:
1. The company had 4.728 million shares of common stock in the underwritten public offering.
2. The share price was $2.75 per share, which grossed around $13 million before deducting underwriting discounts and commissions, and other offering expenses.
3. The underwriter fully exercised its over-allotment option to purchase another 709,200 shares, with gross proceeds at $2 million.
4. The over-allotment closing is expected to be completed on or around Feb. 13.
5. AxoGen plans to use the proceeds for an expanded sales force, surgeon education programs and general corporate process.
More articles on orthopedic devices:
OsteoMed launches ankle fusion plating system
Mesoblast gets patent for mesenchymal precursor cell technology—7 things to know
K2M closes follow-on offering with $35M
